Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA (FRA:MRK) in a report published on Tuesday, February 5th. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other analysts also recently issued reports on MRK. Deutsche Bank set a €93.00 ($108.14) price objective on shares of Merck KGaA and gave the stock a neutral rating in a report on Tuesday, October 30th. Kepler Capital Markets set a €108.00 ($125.58) price objective on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, December 12th. JPMorgan Chase & Co. set a €95.00 ($110.47) price objective on shares of Merck KGaA and gave the stock a neutral rating in a report on Tuesday, November 27th. Morgan Stanley set a €88.00 ($102.33) price objective on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, December 14th. Finally, Commerzbank set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, November 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the stock. Merck KGaA currently has an average rating of Hold and an average price target of €98.80 ($114.88).
FRA:MRK traded up €1.76 ($2.05) during trading hours on Tuesday, hitting €92.54 ($107.60). The stock had a trading volume of 721,278 shares. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: Bond
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.